Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 3
1998 3
1999 4
2000 6
2001 7
2002 8
2003 10
2004 19
2005 12
2006 14
2007 14
2008 15
2009 16
2010 22
2011 12
2012 7
2013 10
2014 11
2015 9
2016 8
2017 6
2018 13
2019 4
2020 11
2021 20
2022 9
2023 8
2024 16
2025 23
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Entacapone.
Müller T. Müller T. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):983-93. doi: 10.1517/17425255.2010.502167. Expert Opin Drug Metab Toxicol. 2010. PMID: 20572781 Review.
The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs LD half-life and avoids troughs. ...TAKE HOME MESSAGE: These pharmacokinetic data may explain the failure of the STRIDE-PD study, whi …
The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs …
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee. Fox SH, et al. Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570866 Review.
OBJECTIVE: The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). BACKGROUND: The Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments of PD we …
OBJECTIVE: The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's dis …
Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
de Bie RMA, Katzenschlager R, Swinnen BEKS, Peball M, Lim SY, Mestre TA, Perez Lloret S, Coelho M, Aquino C, Tan AH, Bruno V, Dijk JM, Heim B, Lin CH, Kauppila LA, Litvan I, Spijker R, Seppi K, Costa J, Sampaio C, Fox SH, Silverdale MA. de Bie RMA, et al. Mov Disord. 2025 May;40(5):776-794. doi: 10.1002/mds.30162. Epub 2025 Mar 8. Mov Disord. 2025. PMID: 40055961 Free PMC article. Review.
OBJECTIVE: To update evidence-based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD). BACKGROUND: The International Parkinson and Movement Disorder Society (MDS) Evidence Based Medicine in Movement Disorders Committee recommendations for …
OBJECTIVE: To update evidence-based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD). BACKGROUND: …
Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R. Cacabelos R. Int J Mol Sci. 2017 Mar 4;18(3):551. doi: 10.3390/ijms18030551. Int J Mol Sci. 2017. PMID: 28273839 Free PMC article. Review.
Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other symptomatic treatments including dopamine agonists (amantadine, apomorphine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, ropi …
Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other sym …
Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA. Hauser RA. Neurology. 2004 Jan 13;62(1 Suppl 1):S64-71. doi: 10.1212/wnl.62.1_suppl_1.s64. Neurology. 2004. PMID: 14718682 Clinical Trial.
Most PD patients taking levodopa/carbidopa immediate-release (IR) plus entacapone can be directly switched to the corresponding dose Stalevo product. For fluctuating PD patients taking levodopa/carbidopa IR without entacapone, switching to the correspo …
Most PD patients taking levodopa/carbidopa immediate-release (IR) plus entacapone can be directly switched to the correspondin …
L-3,4-Dihydroxy-6-[18F]fluorophenylalanine.
Leung K. Leung K. 2005 Mar 21 [updated 2011 Dec 21]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2005 Mar 21 [updated 2011 Dec 21]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641250 Free Books & Documents. Review.
Parkinson's disease (PD) is associated with a loss of dopamine-containing neurons in striatum of the brain (1, 2). PD is caused by a shortage of dopamine. Dopamine, a neurotransmitter, plays an important role in the mediation of movement, cognition and emotion. ...
Parkinson's disease (PD) is associated with a loss of dopamine-containing neurons in striatum of the brain (1, 2). PD is cause …
Catechol-O-methyltransferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson's disease.
Poewe W. Poewe W. Eur J Neurol. 2023 Nov;30 Suppl 2:9-14. doi: 10.1111/ene.15993. Eur J Neurol. 2023. PMID: 37493495 Review.
Adjunct therapy with the catechol-O-methyltransferase inhibitor entacapone is a first-line approach to treat wearing-off type motor fluctuations in levodopa-treated Parkinson's disease (PD) patients. ...Additional trials have tested the efficacy of adjunct entaca …
Adjunct therapy with the catechol-O-methyltransferase inhibitor entacapone is a first-line approach to treat wearing-off type motor f …
Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance.
Nyholm D, Jost WH. Nyholm D, et al. Ther Adv Neurol Disord. 2022 Jun 26;15:17562864221108018. doi: 10.1177/17562864221108018. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 35785401 Free PMC article. Review.
As Parkinson's disease (PD) progresses, treatment needs to be adapted to maintain symptom control. Once patients develop advanced PD, an optimised regimen of oral and transdermal medications may no longer provide adequate relief of OFF periods and motor complication …
As Parkinson's disease (PD) progresses, treatment needs to be adapted to maintain symptom control. Once patients develop advanced …
Entacapone in the treatment of Parkinson's disease.
Schrag A. Schrag A. Lancet Neurol. 2005 Jun;4(6):366-70. doi: 10.1016/S1474-4422(05)70098-3. Lancet Neurol. 2005. PMID: 15907741 Review.
: Clinical studies are underway to address the hypothesis that motor complications in PD can be delayed if entacapone is given from the start of treatment. Until the results of these trials are available, entacapone is indicated as a useful adjunct to levodop …
: Clinical studies are underway to address the hypothesis that motor complications in PD can be delayed if entacapone is given …
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Liao X, et al. Neurol Sci. 2020 Aug;41(8):2045-2054. doi: 10.1007/s10072-020-04303-x. Epub 2020 Mar 11. Neurol Sci. 2020. PMID: 32162166 Review.
Treatment of Parkinson's disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and safety of LCE in the treatment of early Parkinson's disease (PD) still need to be assessed. Our objective was to do a meta-analysis …
Treatment of Parkinson's disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and …
301 results